Tag Archive for: COPD

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

/in

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation   Turin, Italy […]

Read more

Verona Pharma: Preparing a potentially novel COPD medicine for market

/in

A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application  to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In the latest episode of Optimum Perspectives podcast, Eva Haas caught up with Chris Martin, Senior Vice President of Commercial, who […]

Read more

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

/in

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2023 (GLOBE NEWSWIRE) […]

Read more

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

/in

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company […]

Read more

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

/in

Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 07, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a […]

Read more
© Optimum Strategic Communications.